
News|Articles|April 1, 2003
Certain prescription cough syrups to be pulled from the market per FDAruling
An ingredient in dozens of cough syrups, which the FDA says is not dangerous,never underwent the current drug approval process because it was introducedbefore FDA efficacy guidelines were in place. The drug, extended-releaseguaifenesin, is marketed as an expectorant by 66 companies in prescriptioncough syrups.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Spain can offer a healthcare lesson to the United States
2
MHE Week in Review – COVID Shingles Risk, FDA Removes Menopause Therapy Warning and More
3
Keytruda shows survival edge over Tecentriq, Opdivo in older patients with lung cancer
4
Two studies underscore need for more effective, bladder-sparing therapies in high-risk cancer
5

















































